J Breast Cancer.  2014 Dec;17(4):363-369. 10.4048/jbc.2014.17.4.363.

Risk of Trastuzumab-Related Cardiotoxicity in Early Breast Cancer Patients: A Prospective Observational Study

Affiliations
  • 1Department of Cardiology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China. xiaozhongzhang06@sina.com
  • 2Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.

Abstract

PURPOSE
In the present study, we investigated the incidence of cardiotoxicity within 5 years of trastuzumab treatment and evaluated potential risk factors in clinical practice.
METHODS
The study cohort included 415 patients diagnosed with early breast cancer (EBC). Cardiotoxicity incidence was evaluated in patients receiving trastuzumab and those who did not. Multivariate Cox proportional hazards regression models were used to estimate hazard ratios and 95% confidence intervals of potential risk factors for trastuzumab-related cardiotoxicity after appropriate adjustments.
RESULTS
Incidence of cardiotoxicity in patients treated with trastuzumab was significantly higher than that in controls (23.7% vs. 10.8%, p<0.001). This result was adjusted for factors that might increase the risk of cardiotoxicity, such as history of coronary artery diseases or the use of anthracyclines for more than four cycles.
CONCLUSION
Our findings indicated that treatment with trastuzumab was strongly associated with cardiotoxicity in EBC patients.

Keyword

Breast neoplasms; Cardiotoxicity; Trastuzumab

MeSH Terms

Anthracyclines
Breast Neoplasms*
Cohort Studies
Coronary Artery Disease
Humans
Incidence
Observational Study*
Prospective Studies*
Risk Factors
Trastuzumab
Anthracyclines
Full Text Links
  • JBC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr